Galcanezumab

Galcanezumab
Monoclonal antibody
Type Whole antibody
Source Human
Target CALCA, CALCB
Clinical data
Trade names Emgality
Synonyms LY2951742
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6392H9854N1686O2018S46
Molar mass 144.1 kDa

Galcanezumab, marketed under the trade name Emgality, is a humanized monoclonal antibody used for the prevention of migraine.[1][2] It is directed against calcitonin-related polypeptides alpha and beta.

This drug was developed by Eli Lilly & Co. As of July 2017.[3] The drug was approved by the US FDA in September 2018, becoming the third marketed CGRP inhibitor for the United States.[4]

See also

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Galcanezumab, American Medical Association.
  2. ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
  3. ↑ H. Spreitzer (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017).
  4. ↑ "US FDA approves Lilly migraine drug at a price that is the same as its rivals". CNBC. Reuters. 28 September 2018. Retrieved 29 September 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.